BRPI0610090A2 - terapia de combinaÇço compreendendo diaril urÉias para tratar doenÇas - Google Patents
terapia de combinaÇço compreendendo diaril urÉias para tratar doenÇasInfo
- Publication number
- BRPI0610090A2 BRPI0610090A2 BRPI0610090-2A BRPI0610090A BRPI0610090A2 BR PI0610090 A2 BRPI0610090 A2 BR PI0610090A2 BR PI0610090 A BRPI0610090 A BR PI0610090A BR PI0610090 A2 BRPI0610090 A2 BR PI0610090A2
- Authority
- BR
- Brazil
- Prior art keywords
- ureas
- combination therapy
- treat diseases
- diary
- urea compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05011478 | 2005-05-27 | ||
| EP05011476 | 2005-05-27 | ||
| EP05011475 | 2005-05-27 | ||
| PCT/EP2006/004523 WO2006125539A2 (en) | 2005-05-27 | 2006-05-13 | Combination therapy comprising diaryl ureas for treating diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0610090A2 true BRPI0610090A2 (pt) | 2008-12-09 |
Family
ID=37052960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0610090-2A BRPI0610090A2 (pt) | 2005-05-27 | 2006-05-13 | terapia de combinaÇço compreendendo diaril urÉias para tratar doenÇas |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20090306020A1 (enExample) |
| EP (1) | EP1888065A2 (enExample) |
| JP (1) | JP2008545670A (enExample) |
| KR (1) | KR20080012902A (enExample) |
| AU (1) | AU2006251428A1 (enExample) |
| BR (1) | BRPI0610090A2 (enExample) |
| CA (1) | CA2609387A1 (enExample) |
| IL (1) | IL187085A0 (enExample) |
| MX (1) | MX2007014920A (enExample) |
| WO (1) | WO2006125539A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE538794T1 (de) | 1999-01-13 | 2012-01-15 | Bayer Healthcare Llc | Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| MXPA04007832A (es) | 2002-02-11 | 2005-09-08 | Bayer Pharmaceuticals Corp | Aril-ureas con actividad inhibitoria de angiogenesis. |
| UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
| EP1636585B2 (en) | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl ureas with kinase inhibiting activity |
| HRP20060073B1 (hr) | 2003-07-23 | 2014-03-14 | Bayer Healthcare Llc | Fluoro supstituirana omega-karboksiaril difenil urea za lijeäśenje i prevenciju bolesti i stanja |
| US20110008327A1 (en) | 2004-03-29 | 2011-01-13 | Cheng Jin Q | Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof |
| CN104688697A (zh) * | 2005-03-07 | 2015-06-10 | 拜尔健康护理有限责任公司 | 用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物 |
| AR062927A1 (es) * | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
| TW200835507A (en) * | 2006-12-05 | 2008-09-01 | Vioquest Pharmaceuticals Inc | Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof |
| CA2675980C (en) | 2007-01-19 | 2016-06-21 | Bayer Healthcare Llc | Use of dast for treatment of cancers with acquired resistance to kit inhibitors |
| US7947723B2 (en) | 2008-02-01 | 2011-05-24 | Spelman College | Synthesis and anti-proliferative effect of benzimidazole derivatives |
| JP2011516553A (ja) * | 2008-04-09 | 2011-05-26 | ダウ グローバル テクノロジーズ リミティド ライアビリティ カンパニー | ジクロロヒドリン類を回収する多段法及び装置 |
| TW201012467A (en) * | 2008-09-16 | 2010-04-01 | Taiho Pharmaceutical Co Ltd | Antitumor agent containing 4-[[3,5-bis(trimethylsilyl)benzoyl]amino]benzoic acid |
| BRPI1015940A2 (pt) * | 2009-04-09 | 2016-04-19 | Oncothyreon Inc | métodos e composições de inibidores de pi-3 quinase para tratar fibrose |
| US9556426B2 (en) | 2009-09-16 | 2017-01-31 | Celgene Avilomics Research, Inc. | Protein kinase conjugates and inhibitors |
| CN102812167A (zh) | 2009-12-30 | 2012-12-05 | 阿维拉制药公司 | 蛋白的配体-介导的共价修饰 |
| ES2385276B1 (es) * | 2010-02-25 | 2013-07-05 | Universidad Del País Vasco | Compuestos para el tratamiento de alzheimer. |
| WO2012012404A1 (en) | 2010-07-19 | 2012-01-26 | Bayer Healthcare Llc | Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| RU2722784C2 (ru) | 2013-12-20 | 2020-06-03 | Байомед Вэлли Дискавериз, Инк. | Лечение злокачественных опухолей с применением комбинаций ингибиторов erk и raf |
| WO2015095842A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
| CN114751899B (zh) * | 2022-04-24 | 2024-03-29 | 贵州医科大学 | 一种二芳基脲类mTOR激酶抑制剂及其药物组合物和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5378725A (en) * | 1993-07-19 | 1995-01-03 | The Arizona Board Of Regents | Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof |
| WO2000042012A1 (en) * | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
| MXPA04007832A (es) * | 2002-02-11 | 2005-09-08 | Bayer Pharmaceuticals Corp | Aril-ureas con actividad inhibitoria de angiogenesis. |
| WO2003086279A2 (en) * | 2002-04-08 | 2003-10-23 | Merck & Co., Inc. | Inhibitors of akt activity |
| HRP20060073B1 (hr) * | 2003-07-23 | 2014-03-14 | Bayer Healthcare Llc | Fluoro supstituirana omega-karboksiaril difenil urea za lijeäśenje i prevenciju bolesti i stanja |
| US20050267060A1 (en) * | 2004-03-19 | 2005-12-01 | The Penn State Research Foundation | Combinatorial methods and compositions for treatment of melanoma |
| ATE517901T1 (de) * | 2004-09-06 | 2011-08-15 | Bayer Schering Pharma Ag | Pyrazolopyrimidine als hemmer der proteinkinase b (akt) |
-
2006
- 2006-05-13 JP JP2008512729A patent/JP2008545670A/ja active Pending
- 2006-05-13 BR BRPI0610090-2A patent/BRPI0610090A2/pt not_active Application Discontinuation
- 2006-05-13 MX MX2007014920A patent/MX2007014920A/es not_active Application Discontinuation
- 2006-05-13 EP EP06761913A patent/EP1888065A2/en not_active Withdrawn
- 2006-05-13 KR KR1020077027599A patent/KR20080012902A/ko not_active Withdrawn
- 2006-05-13 US US11/920,952 patent/US20090306020A1/en not_active Abandoned
- 2006-05-13 CA CA002609387A patent/CA2609387A1/en not_active Abandoned
- 2006-05-13 AU AU2006251428A patent/AU2006251428A1/en not_active Abandoned
- 2006-05-13 WO PCT/EP2006/004523 patent/WO2006125539A2/en not_active Ceased
-
2007
- 2007-11-01 IL IL187085A patent/IL187085A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006251428A1 (en) | 2006-11-30 |
| EP1888065A2 (en) | 2008-02-20 |
| MX2007014920A (es) | 2008-04-09 |
| WO2006125539A2 (en) | 2006-11-30 |
| CA2609387A1 (en) | 2006-11-30 |
| WO2006125539A3 (en) | 2007-03-08 |
| US20090306020A1 (en) | 2009-12-10 |
| JP2008545670A (ja) | 2008-12-18 |
| IL187085A0 (en) | 2008-08-07 |
| KR20080012902A (ko) | 2008-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0610090A2 (pt) | terapia de combinaÇço compreendendo diaril urÉias para tratar doenÇas | |
| ECSP10010042A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119 | |
| PA8637201A1 (es) | Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa | |
| BRPI0808775A2 (pt) | compostos e composições como moduladores de atividade de gpr119 | |
| TW200744586A (en) | Therapeutic compounds | |
| BRPI0606891A2 (pt) | anticorpos dr5 e usos dos mesmos | |
| AR063628A1 (es) | Compuestos de piridinona utiles para el tratamiento de cancer | |
| ECSP105178A (es) | Compuestos de aril urea en combinación con otros agentes citostáticos o citotóxicos para el tratamiento de cáncer en humanos | |
| MX2009007944A (es) | Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium. | |
| MX2011013176A (es) | Motivos de modificación química para inhibidores y miméticos del miarn. | |
| HN2006009702A (es) | Composicion farmaceutica para el tratamiento del cancer | |
| ECSP088749A (es) | Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos | |
| MX2011008899A (es) | Nuevas orto-aminoamidas para el tratamiento del cancer. | |
| MX2009002054A (es) | Metodos para inhibir angiogenesis y tratamiento contra enfermedades asociadas con angiogenesis. | |
| BRPI0820668A2 (pt) | Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina | |
| CL2008002185A1 (es) | Compuestos derivados de pirimidina, inhibidores de fosfatidilinositol-3-cinasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades resapiratorias, alergias, inflamacion, cancer, entre otras enfermedades. | |
| AR056801A1 (es) | Terapia combinada anti- proliferativa con determinados agentes quimioterapeuticos basados en platino e inhibidores de egfr o analogos de pirimidina | |
| DE602006016449D1 (enExample) | ||
| CO2022016754A2 (es) | Moléculas de fijación para el tratamiento de cáncer | |
| BRPI0507626A (pt) | compostos e composiçoes como moduladores de lxr | |
| UY29161A1 (es) | Nuevos heterociclos | |
| MX2008002166A (es) | Compuestos y composiciones como mimeticos de trombopoietina (tpo). | |
| MX2010000223A (es) | Compuestos de triazina novedosos para el tratamiento de cancer. | |
| WO2010031708A3 (en) | Ortho-aminoanilides for the treatment of cancer | |
| DE602006012313D1 (de) | Kombination aus pyrimidylaminobenzamid-verbindungen und imatinib zur behandlung oder verhinderung proliferativer erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |